

**Clinical Trials Summary for out of hours  
Important Reference**

<b>Acronym study title</b>	<b>heredERA</b>
<b>Study Details</b>	A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER
<b>Principal Investigator PI Sub PI's</b>	<b>PI—Dr Hogg Sub PI-Dr Young</b>
<b>Research Nurse Team</b>	<b>Haiyan Huang</b>
<b>Drug therapy</b>	<b>Phesgo Giredestrant</b>
<b>In the event that a patient calls this hotline for advise</b>	Please treat as per clinical protocols and inform the clinical and research teams. Chemotherapy helpline—stated in patients chemotherapy book.